- Home
- CMRX
CMRX
Chimerix Inc.
as 02-21-2025 4:00pm EST
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Upcoming Earnings Alert:
Get ready for potential market movements as Chimerix Inc. CMRX prepares to release earnings report on 27 Feb 2025.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 394.1M | IPO Year: | 2013 |
| Target Price: | $8.50 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.75 - $5.53 | Next Earning Date: | 02-27-2025 |
| Revenue: | $159,000 | Revenue Growth: | -85.98% |
| Revenue Growth (this year): | -27.59% | Revenue Growth (next year): | 1690.28% |
Stock Insider Trading Activity of Chimerix Inc. (CMRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Andriole Michael T. | CMRX | PRESIDENT AND CEO | Feb 13 '25 | Sell | $4.52 | 7,370 | $33,282.18 | 609,603 | |
| LaSpaluto Michelle | CMRX | CHIEF FINANCIAL OFFICER | Feb 13 '25 | Sell | $4.51 | 2,260 | $10,195.54 | 172,977 | |
| Alrutz Michael Albert | CMRX | SVP AND GENERAL COUNSEL | Feb 13 '25 | Sell | $4.52 | 1,600 | $7,226.40 | 213,596 | |
| Melemed Allen S. | CMRX | CHIEF MEDICAL OFFICER | Feb 13 '25 | Sell | $4.50 | 3,065 | $13,798.63 | 152,875 | |
| Andriole Michael T. | CMRX | PRESIDENT AND CEO | Jan 30 '25 | Sell | $4.10 | 2,350 | $9,636.18 | 609,603 | |
| LaSpaluto Michelle | CMRX | CHIEF FINANCIAL OFFICER | Jan 30 '25 | Sell | $4.11 | 1,015 | $4,171.65 | 172,977 | |
| Jakeman David | CMRX | VP OF FINANCE AND ACCOUNTING | Jan 30 '25 | Sell | $4.10 | 2,800 | $11,470.20 | 149,287 |
Latest Chimerix Inc. News
CMRX Breaking Stock News: Dive into CMRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Exploring Three High Growth Tech Stocks in the United States
GlobeNewswire
4 days ago
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
4 days ago
Sector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires
4 days ago
Sector Update: Health Care
MT Newswires
4 days ago
Chimerix Says FDA Grants Priority Review for New Drug Application of Cancer Treatment Dordaviprone; Shares Rise
MT Newswires
4 days ago
Wedbush Adjusts Price Target on Chimerix to $7 From $6, Keeps Outperform Rating
GlobeNewswire
4 days ago
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
Simply Wall St.
6 days ago
Metalpha Technology Holding And 2 Other US Penny Stocks To Monitor
Compare CMRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CMRX Chimerix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.